Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
48 hedge funds and large institutions have $77.2M invested in Regulus Therapeutics in 2017 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 18 increasing their positions, 13 reducing their positions, and 8 closing their positions.
244% more capital invested
Capital invested by funds: $22.4M → $77.2M (+$54.8M)
38% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 13
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
4% more funds holding
Funds holding: 46 → 48 (+2)
0.14% more ownership
Funds ownership: 0.36% → 0.5% (+0.14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$11.5M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$10.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.96M |
| 4 |
BC
Broadfin Capital
New York
|
+$4.5M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
+$2.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$363K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$246K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$216K |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
-$164K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$144K |
RGLS Hedge Fund Activity: Q3 2017 in Review
48 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q3 2017, worth a combined $77.2M — up 244% from $22.4M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new RGLS positions and 8 closed out — a net gain of 3 holders — while 18 added to existing stakes and 13 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $11.5M. The largest seller was Goldman Sachs, exiting entirely with an estimated $363K sold.
- 48 institutional investors held Regulus Therapeutics (RGLS) as of Q3 2017, up from 46 in Q2 2017.
- Funds reported $77.2M of Regulus Therapeutics stock for Q3 2017, up 244% quarter-over-quarter.
- 11 funds opened new Regulus Therapeutics positions in Q3 2017 and 8 closed out, a net change of +3 holders.
- The largest Regulus Therapeutics buyer in Q3 2017 was NEA Management Company, an estimated $11.5M added.
- The largest Regulus Therapeutics seller in Q3 2017 was Goldman Sachs, an estimated $363K sold.
Based on aggregated 13F filings for Q3 2017.